Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Generic Antiepilepsy Drugs Have Minimal Differences: Study

By Drug Discovery Trends Editor | December 10, 2014

Michael Privitera, MD, is a professor in the neurology dept. and director of the Epilepsy Center at the UC Neuroscience Institute (Credit: University of Cincinnati) A comparison of two of the most disparate approved generic antiepileptic drugs found minimal differences when compared under rigorous testing procedures in people with epilepsy, according to research presented by a University of Cincinnati (UC) clinician-researcher.
 
In addition, the research showed, no subjects had serious adverse effects or loss of seizure control when switching from one drug to the other.
 
Michael Privitera, MD, a professor in the UC Department of Neurology and Rehabilitation Medicine and director of the Epilepsy Center at the UC Neuroscience Institute, presented the research at the annual meeting of the American Epilepsy Society in Seattle.
 
Privitera and colleagues at UC, the University of Rochester and four other centers received $2.6 million from the U.S. Food and Drug Administration in 2013 to study generic equivalents for the U.S. Food and Drug Administration-approved antiepileptic drug lamotrigine (marketed by GlaxoSmithKline as Lamictal), as part of an effort to provide the FDA with data that could lead to new regulations related to approval of new generic drugs. The American Epilepsy Society and the Epilepsy Foundation also contributed to the study. (Privitera reports no conflicts of interest.)
 
The study, along with a separate effort comparing two generic copies with Lamictal, is known as EQUIGEN, or EQUIvalence among GENeric AEDS (antiepileptic drugs).
 
“Some physicians and patients perceive that generic antiepileptic drugs are not always equivalent to brand products,” says Privitera, who noted that the FDA currently approves generic drugs by requiring studies on normal volunteers (i.e., those who don’t have epilepsy) and who take just one dose of the generic drug followed by a series of blood tests. 
 
“We designed this study to address those concerns and mimic real-life circumstances for epilepsy patients.”
 
Several studies of thousands of patients have suggested that hospitalizations and doctor visits are more common in people with epilepsy after switching to generic drugs. However, these studies did not carefully measure blood levels or control for other factors. The EQUIGEN studies were designed to control for missed doses and rigorously measure blood levels, obtaining blood levels over 12 hours.
 
To meet FDA standards, generic versions of a brand name drug must have 80% to 125% bioequivalence of the original drug. Privitera and his colleagues tested two generics that had achieved that standard in single-dose studies with normal volunteers: one generic on the low end, and one on the high end. 
 
“That way, we were testing the worst-case scenario,” Privitera says: “That the patient could go to a pharmacy and get the generic product at the high end of the bioequivalency scale, then go back the next time and get the product on the low end of the scale.”
 
The researchers divided study participants (33 out of 35 original participants completed the study) into two groups, with each group switching generic copies twice over four test periods. Patients also continued their usual medications, including antiepilepsy drugs. At the end of each two-week test period, the participants underwent extensive blood level monitoring.
 
“None of the subjects had any serious adverse events or loss of seizure control after crossover between generic products,” Privitera reports, adding that the results showed that chronic dosing studies are feasible and that subjects are highly compliant. (There were no dropouts due to lack of compliance.)
 
In the other EQUIGEN study, researchers are comparing the two generic copies with Lamictal, the brand-name version of lamotrigine. Participants take each medicine twice during the study period. This is a “single dose” study, in which patients take a single dose of generic lamotrigine in addition to their regular antiepileptic drugs and then have rigorous blood level testing over a 96-hour period.
 
Source: University of Cincinnati 

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE